CJC-1295 No DAC 5mg

Description

CJC-1295 without DAC 5 mg, commonly referred to as Modified GRF 1-29, is a research-grade synthetic peptide supplied in lyophilized form for controlled laboratory investigations involving growth hormone-releasing hormone signaling and neuroendocrine receptor activity.

Modified GRF 1-29 is based on the biologically active N-terminal 29-amino-acid sequence of growth hormone-releasing hormone. Its structure incorporates targeted amino acid substitutions designed to improve stability while preserving activity at the growth hormone-releasing hormone receptor.

Unlike CJC-1295 with DAC, this peptide does not contain an albumin-binding Drug Affinity Complex. This distinction makes it useful for researchers studying shorter-duration receptor activation, temporal signaling patterns, peptide stability, and the effects of structural modification on GHRH analog activity.

In laboratory models, activation of the GHRH receptor is associated with G protein-mediated signaling and cyclic adenosine monophosphate production. Researchers may use Modified GRF 1-29 to investigate receptor binding, intracellular signaling, pituitary somatotroph activity, concentration-response relationships, and downstream neuroendocrine pathways.

The 5 mg presentation is suitable for preliminary investigations, assay development, receptor-response testing, time-course experiments, and comparative studies involving modified and native GHRH sequences.

Each PEPTEX Labs production lot is manufactured under controlled conditions and subject to quality testing. Testing may include HPLC purity analysis, mass spectrometry identity verification, net-content testing, and endotoxin analysis, depending on the individual batch.

This product is supplied exclusively for qualified laboratory research. It is not intended for human or veterinary use, clinical administration, or therapeutic application.